Skip to main content

Atopic Dermatitis News

News
12/20/2022
Jolynn Tumolo
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
12/08/2022
Jolynn Tumolo
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
11/22/2022
Jolynn Tumolo
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
11/17/2022
Jolynn Tumolo
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
News
10/28/2022
Maria Asimopoulos
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
10/13/2022
Edan Stanley
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
09/09/2022
Jolynn Tumolo
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
08/26/2022
Edan Stanley
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
07/29/2022
Maria Asimopoulos
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
07/22/2022
Jolynn Tumolo
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care